person · Reporting owner

SHERMAN JEFFREY W

Disclosed activity across 5 companies

Tapewire entity: 45619
SEC CIK: 0001230482

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Larimar Therapeutics, Inc.LRMR · Entity 5634	Director	May 19, 2026	May 20, 2026
Strongbridge Biopharma plcSBBP · Entity 131608	Director	October 05, 2021	October 06, 2021
XERIS PHARMACEUTICALS INCXERS · Entity 134906	Director	October 05, 2021	October 05, 2021
Xeris Biopharma Holdings, Inc.XERS · Entity 4670	Director	August 28, 2025	August 29, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Larimar Therapeutics, Inc.

Report date May 19, 2026 · Filed May 20, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.33 · Expires 2036-05-19	Direct	55,150	Reported balance After 2026-05-19 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-19 · Grant · Acquired 55,150 · Balance 55,150 F1: The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

Filing footnotes · ownership attribution and instrument terms

F1: The options vest on the earlier of (a) May 19, 2027 or (b) the date of the Company's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service on the Board of Directors of the Company.

Strongbridge Biopharma plc

Report date October 05, 2021 · Filed October 06, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	0	Reported balance After 2021-10-05 transaction · row 1 1 source row Row 1 · 2021-10-05 · Disposition to issuer · Disposed 64,258 · Balance 0 F1: Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. ("HoldCo") pursuant to the Transaction Agreement (the "Agreement"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a "CVR") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-10-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-10-05 · Disposition to issuer · Disposed 140,000 · Balance 0 F2: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option.

Filing footnotes · ownership attribution and instrument terms

F1: Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. ("HoldCo") pursuant to the Transaction Agreement (the "Agreement"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a "CVR") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election.

F2: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option.

XERIS PHARMACEUTICALS INC

Report date October 05, 2021 · Filed October 05, 2021

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.50 · Expires 2028-05-15	Direct	Reported balance After 2021-10-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-10-05 · Disposition to issuer · Disposed 19,650 · Balance 0 F1: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F3: These options are fully vested as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2029-02-27	Direct	Reported balance After 2021-10-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-10-05 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F3: These options are fully vested as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.68 · Expires 2030-06-04	Direct	Reported balance After 2021-10-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-10-05 · Disposition to issuer · Disposed 11,228 · Balance 0 F1: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F3: These options are fully vested as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.90 · Expires 2031-06-08	Direct	Reported balance After 2021-10-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-10-05 · Disposition to issuer · Disposed 11,228 · Balance 0 F1: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option. F4: Such options will vest in full upon the earlier to occur of June 8, 2022 or the date of the Company's next annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among the Issuer ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), Xeris Biopharma Holdings, Inc. ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction").

F2: (Continued from Footnote 1) At the effective time of the Merger (the "Effective Time"), each option to purchase shares of Xeris common stock (the "Xeris Option") that was outstanding immediately prior to the Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option"), on the same terms and conditions including any applicable vesting and exercisability requirements) as were applicable to such Xeris Option immediately prior to the Effective Time, including that the number of shares of HoldCo common stock subject to the HoldCo Option is equal to the number of shares that were subject to the Xeris Option and the exercise price applicable to the HoldCo Option is the same as applied to the Xeris Option.

F3: These options are fully vested as of the date hereof.

F4: Such options will vest in full upon the earlier to occur of June 8, 2022 or the date of the Company's next annual meeting of stockholders.

Xeris Biopharma Holdings, Inc.

Report date August 28, 2025 · Filed August 29, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	219,188	Ending reported balance After 2025-08-28 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2025-08-28 · Exercise / conversion · Acquired 47,040 · Balance 261,420 Row 2 · 2025-08-28 · Sale · Disposed 42,232 · Balance 219,188 F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.920 to $7.935, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.66 · Expires 2026-10-01	Direct	0	Reported balance After 2025-08-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-08-28 · Exercise / conversion · Disposed 47,040 · Balance 0 F3: On October 1, 2016, the reporting person was granted an option to purchase shares of Strongbridge Biopharma plc ("Strongbridge") which were assumed by Issuer in connection with the acquisition of Strongbridge. The options vested in full on October 5, 2021.
Common StockSEC Table I · non-derivative	IndirectBy: JEFFREY W SHERMAN LIVING TRUST U/A DTD 03/21/2001	5,400	Reported balance Holding disclosure · report date 2025-08-28 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 5,400 F2: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.920 to $7.935, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F3: On October 1, 2016, the reporting person was granted an option to purchase shares of Strongbridge Biopharma plc ("Strongbridge") which were assumed by Issuer in connection with the acquisition of Strongbridge. The options vested in full on October 5, 2021.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Horizon Therapeutics Public Ltd Co

Report date October 06, 2023 · Filed October 06, 2023

Section 16 reporting ended · disclosed 2023-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	Reported balance After 2023-10-06 transaction · row 1 1 source row Row 1 · 2023-10-06 · Disposition to issuer · Disposed 2,655 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
Ordinary SharesSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2023-10-06 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2023-10-06 · Disposition to issuer · Disposed 105,808 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). F2: The Ordinary Shares are held in the name of the Jeffrey W. Sherman 2020 Gift Trust, of which the reporting person's spouse is the Trustee.
Ordinary SharesSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2023-10-06 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2023-10-06 · Disposition to issuer · Disposed 80,944 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration"). F3: The Ordinary Shares are held in the Jeffrey W. Sherman Living Trust.
Ordinary SharesSEC Table I · non-derivative	IndirectBy Spouse	Reported balance After 2023-10-06 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 4 · 2023-10-06 · Disposition to issuer · Disposed 45,352 · Balance 0 F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.14 · Expires 2025-03-23	Direct	Reported balance After 2023-10-06 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-10-06 · Disposition to issuer · Disposed 164,469 · Balance 0 F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option. F4: The Option (as defined in footnote 5 to this Form 4) is fully vested.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-10-06 · Disposition to issuer · Disposed 9,314 · Balance 0 F6: Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs, (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F7: The Ordinary Shares subject to the RSUs vest on January 5, 2024.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-10-06 · Disposition to issuer · Disposed 12,696 · Balance 0 F6: Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs, (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F9: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2022.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-10-06 · Disposition to issuer · Disposed 18,397 · Balance 0 F6: Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F8: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs, (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme. F10: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2023.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-10-06 · Disposition to issuer · Disposed 12,226 · Balance 0 F6: Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F12: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F11: The Ordinary Shares subject to the PSUs vest on January 5, 2024.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-10-06 · Disposition to issuer · Disposed 4,654 · Balance 0 F6: Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F12: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F11: The Ordinary Shares subject to the PSUs vest on January 5, 2024.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2023-10-06 · Disposition to issuer · Disposed 27,942 · Balance 0 F6: Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F12: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F11: The Ordinary Shares subject to the PSUs vest on January 5, 2024.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2023-10-06 · Disposition to issuer · Disposed 3,809 · Balance 0 F6: Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F12: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F13: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2024 and the remaining shares vest on January 5, 2025.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2023-10-06 · Disposition to issuer · Disposed 11,426 · Balance 0 F6: Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F12: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F14: The Ordinary Shares subject to the PSUs vest on January 5, 2025.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2023-10-06 · Disposition to issuer · Disposed 19,044 · Balance 0 F6: Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F12: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F14: The Ordinary Shares subject to the PSUs vest on January 5, 2025.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2023-10-06 · Disposition to issuer · Disposed 4,599 · Balance 0 F6: Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F12: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F15: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2023-10-06 · Disposition to issuer · Disposed 4,599 · Balance 0 F6: Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F12: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F15: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026.
Performance Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-10-06 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2023-10-06 · Disposition to issuer · Disposed 9,200 · Balance 0 F6: Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer. F12: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration. F16: The Ordinary Shares subject to the PSUs vest on January 5, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects the disposition of ordinary shares of Horizon Therapeutics plc ("Issuer"), nominal value $0.0001 per share ("Ordinary Shares"), in connection with the consummation of the transactions contemplated by the Transaction Agreement (the "Transaction Agreement"), dated as of December 11, 2022, by and among Issuer, Amgen Inc. ("Parent"), and Pillartree Limited, a wholly owned subsidiary of Parent ("Acquirer Sub"), including the consummation of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the "Scheme") pursuant to which Acquirer Sub acquired Issuer. Pursuant to the Transaction Agreement, on October 6, 2023, the effective time of the Scheme (the "Effective Time"), each outstanding Ordinary Share was converted into $116.50 in cash (the "Consideration").

F2: The Ordinary Shares are held in the name of the Jeffrey W. Sherman 2020 Gift Trust, of which the reporting person's spouse is the Trustee.

F3: The Ordinary Shares are held in the Jeffrey W. Sherman Living Trust.

F4: The Option (as defined in footnote 5 to this Form 4) is fully vested.

F5: Reflects the disposition of Issuer's options to purchase Ordinary Shares (each, an "Option") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding Option (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (a) the total number of Ordinary Shares subject to such Option, multiplied by (b) the excess of (i) the Consideration over (ii) the exercise price payable per Ordinary Share under such Option.

F6: Each RSU (as defined in footnote 8 to this Form 4) and PSU (as defined in footnote 12 to this Form 4) represents a contingent right to receive one Ordinary Share of the Issuer.

F7: The Ordinary Shares subject to the RSUs vest on January 5, 2024.

F8: Reflects the disposition of Issuer's restricted stock unit awards, excluding PSUs, (each, a "RSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding RSU (whether or not vested) was assumed and converted into a restricted stock unit (each, a "Parent RSU") denominated in shares of Parent's common stock. The number of shares of Parent's common stock subject to each such Parent RSU was equal to the product (rounded down to the nearest whole number) of (y) the number of shares of Ordinary Shares subject to the RSU immediately prior to the Effective Time multiplied by (z) the ratio equal to (1) the Consideration divided by (2) the volume weighted average of the per share closing price of Parent's common stock on the Nasdaq for five (5) trading days ending on the second business day prior to the completion of the Scheme.

F9: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2022.

F10: The Ordinary Shares subject to the RSUs vest 1/3rd annually on each anniversary of January 5, 2023.

F11: The Ordinary Shares subject to the PSUs vest on January 5, 2024.

F12: Reflects the disposition of Issuer's restricted stock unit awards with performance-based vesting or delivery requirements (each, a "PSU") as contemplated by the Transaction Agreement. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding PSU (whether or not vested) was canceled and converted into the right to receive cash, without interest, in an amount equal to (i) the total number of Ordinary Shares issuable in settlement of such PSU (as determined in accordance with the Transaction Agreement) multiplied by (ii) the Consideration.

F13: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2024 and the remaining shares vest on January 5, 2025.

F14: The Ordinary Shares subject to the PSUs vest on January 5, 2025.

F15: The Ordinary Shares subject to the PSUs vest 2/3rd on January 5, 2025 and the remaining shares vest on January 5, 2026.

F16: The Ordinary Shares subject to the PSUs vest on January 5, 2026.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 28, 2021 Filed Jul 30, 2021 16:27 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Tax withholdingOrdinary Shares	3,215	$102.50	$329,537.50	Disclosure SEC source: 0001209191-21-048791 · doc4.xml · nonDerivative · entry 2 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,157 Read SEC document
July 28, 2021 Filed Jul 30, 2021 16:27 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantOrdinary Shares	7,257	$0.00	$0.00	Disclosure SEC source: 0001209191-21-048791 · doc4.xml · nonDerivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,372 F1 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On July 28, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. Read SEC document
July 01, 2021 Filed Jul 2, 2021 17:02 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	54,789	$95.00	$5,205,097.45	Disclosure SEC source: 0001209191-21-045065 · doc4.xml · nonDerivative · entry 4 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 128,845 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2021. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.00 to $95.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
July 01, 2021 Filed Jul 2, 2021 17:02 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	5,287	$95.00	$502,265.00	Disclosure SEC source: 0001209191-21-045065 · doc4.xml · nonDerivative · entry 3 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,115 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2021. Read SEC document
June 11, 2021 Filed Mar 21, 2022 16:25 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GiftOrdinary Shares	5,287	$0.00	$0.00	Disclosure SEC source: 0001209191-22-020259 · doc4.xml · nonDerivative · entry 4 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,276 Read SEC document
June 11, 2021 Filed Mar 21, 2022 16:25 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GiftOrdinary Shares	5,287	$0.00	$0.00	Disclosure SEC source: 0001209191-22-020259 · doc4.xml · nonDerivative · entry 3 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 44,775 F1 · ownership.nature: The shares are held in the Jeffrey W. Sherman Living Trust. Read SEC document
June 08, 2021 Filed Jun 8, 2021 23:10 UTC	XERIS PHARMACEUTICALS INC XERS · Entity 134906	GrantStock Option (Right to Buy) · Derivative	11,228	$0.00 Strike: $3.90	$0.00	Disclosure SEC source: 0001346302-21-000061 · wf-form4_162319377459775.xml · derivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,228 Underlying: Common Stock · 11,228 shares Expires 2031-06-08 F1 · derivative.exercise_date: Such options will vest in full upon the earlier to occur of June 8, 2022 or the date of the Company's next annual meeting of stockholders. Read SEC document
May 25, 2021 Filed Mar 21, 2022 16:25 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GiftOrdinary Shares	12,304	$0.00	$0.00	Disclosure SEC source: 0001209191-22-020259 · doc4.xml · nonDerivative · entry 2 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 50,062 F1 · ownership.nature: The shares are held in the Jeffrey W. Sherman Living Trust. Read SEC document
May 25, 2021 Filed Mar 21, 2022 16:25 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GiftOrdinary Shares	12,304	$0.00	$0.00	Disclosure SEC source: 0001209191-22-020259 · doc4.xml · nonDerivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,989 Read SEC document
May 18, 2021 Filed May 18, 2021 23:12 UTC	Strongbridge Biopharma plc SBBP · Entity 131608	GrantOrdinary Shares	40,000	$0.00	$0.00	Disclosure SEC source: 0001179110-21-005557 · edgar.xml · nonDerivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,021 F1 · shares: Represents a grant of restricted stock units, which vest in full on May 18, 2022, provided that the Reporting Person continues to serve as a member of the board of directors of the Issuer through that date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
May 14, 2021 Filed May 17, 2021 22:31 UTC	Strongbridge Biopharma plc SBBP · Entity 131608	Tax withholdingOrdinary Shares	18,944	$2.35	$44,518.40	Disclosure SEC source: 0001179110-21-005442 · edgar.xml · nonDerivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,021 F1 · shares: Shares withheld by the Issuer to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units. Read SEC document
March 10, 2021 Filed Jul 2, 2021 17:02 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GiftOrdinary Shares	66,730	$0.00	$0.00	Disclosure SEC source: 0001209191-21-045065 · doc4.xml · nonDerivative · entry 2 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 66,730 Read SEC document
March 10, 2021 Filed Jul 2, 2021 17:02 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GiftOrdinary Shares	66,730	$0.00	$0.00	Disclosure SEC source: 0001209191-21-045065 · doc4.xml · nonDerivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,402 F1 · balance_after: Includes 1,049 ordinary shares of the Issuer acquired by the reporting person on June 1, 2021 pursuant to an employee stock purchase program. Read SEC document
February 17, 2021 Filed Feb 19, 2021 17:00 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantPerformance Restricted Stock Units (PSUs) · Derivative	14,512	$0.00	$0.00	Disclosure SEC source: 0001209191-21-012412 · doc4.xml · derivative · entry 5 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,512 Underlying: Ordinary Shares · 14,512 shares Expires not disclosed F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F3 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met. Two-thirds of the ordinary shares subject to the PSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023. F3 · derivative.exercise_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met. Two-thirds of the ordinary shares subject to the PSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023. F3 · derivative.expiration_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met. Two-thirds of the ordinary shares subject to the PSUs vest on January 5, 2022 and the remaining one-third of the ordinary shares vest on January 5, 2023. Read SEC document
February 17, 2021 Filed Feb 19, 2021 17:00 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantPerformance Restricted Stock Units (PSUs) · Derivative	3,931	$0.00	$0.00	Disclosure SEC source: 0001209191-21-012412 · doc4.xml · derivative · entry 4 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,931 Underlying: Ordinary Shares · 3,931 shares Expires not disclosed F2 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F1 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. F1 · derivative.exercise_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. F1 · derivative.expiration_date: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. Read SEC document
February 17, 2021 Filed Feb 19, 2021 17:00 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Tax withholdingOrdinary Shares	871	$87.17	$75,925.07	Disclosure SEC source: 0001209191-21-012412 · doc4.xml · nonDerivative · entry 2 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,083 Read SEC document
February 17, 2021 Filed Feb 19, 2021 17:00 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantOrdinary Shares	1,965	$0.00	$0.00	Disclosure SEC source: 0001209191-21-012412 · doc4.xml · nonDerivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,954 F1 · kind: On January 3, 2020, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On February 17, 2021, such performance criteria were met, and the PSUs vested as to the number of shares reported in Table I above. The remaining ordinary shares subject to the PSUs vest in equal annual installments on January 5, 2022 and January 5, 2023. Read SEC document
January 21, 2021 Filed Jan 22, 2021 21:00 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionPerformance Restricted Stock Units (PSUs) · Derivative	5,353	$0.00	$0.00	Disclosure SEC source: 0001209191-21-004993 · doc4.xml · derivative · entry 5 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,354 Underlying: Ordinary Shares · 5,353 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each PSU represents a contingent right to receive one ordinary share of the Issuer. F2 · derivative.exercise_date: The shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. F2 · derivative.expiration_date: The shares subject to the PSUs vest in equal annual installments on January 21, 2021 and January 21, 2022. Read SEC document
January 21, 2021 Filed Jan 22, 2021 21:00 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Tax withholdingOrdinary Shares	2,372	$77.43	$183,663.96	Disclosure SEC source: 0001209191-21-004993 · doc4.xml · nonDerivative · entry 4 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,989 Read SEC document
January 21, 2021 Filed Jan 22, 2021 21:00 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionOrdinary Shares	5,353	$0.00	$0.00	Disclosure SEC source: 0001209191-21-004993 · doc4.xml · nonDerivative · entry 3 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 05, 2021 Filed Jan 6, 2021 21:04 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionRestricted Stock Units (RSU) · Derivative	12,094	$0.00	$0.00	Disclosure SEC source: 0001209191-21-002409 · doc4.xml · derivative · entry 8 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,190 Underlying: Ordinary Shares · 12,094 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. F3 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. Read SEC document
January 05, 2021 Filed Jan 6, 2021 21:04 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionRestricted Stock Units (RSU) · Derivative	17,260	$0.00	$0.00	Disclosure SEC source: 0001209191-21-002409 · doc4.xml · derivative · entry 7 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,260 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F5 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. F5 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2018. Read SEC document
January 05, 2021 Filed Jan 6, 2021 21:04 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionRestricted Stock Units (RSU) · Derivative	12,261	$0.00	$0.00	Disclosure SEC source: 0001209191-21-002409 · doc4.xml · derivative · entry 6 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,261 Underlying: Ordinary Shares · 12,261 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. F4 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2019. Read SEC document
January 05, 2021 Filed Jan 6, 2021 21:04 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Tax withholdingOrdinary Shares	45,256	$73.28	$3,316,359.68	Disclosure SEC source: 0001209191-21-002409 · doc4.xml · nonDerivative · entry 3 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,687 Read SEC document
January 05, 2021 Filed Jan 6, 2021 21:04 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantOrdinary Shares	60,313	$0.00	$0.00	Disclosure SEC source: 0001209191-21-002409 · doc4.xml · nonDerivative · entry 2 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,943 F2 · kind: On January 5, 2018 and January 4, 2019, the reporting person was granted performance-based restricted stock units (PSUs) of the Issuer, which vest upon the satisfaction of certain performance criteria. On January 5, 2021, the PSUs vested as to the number of shares reported above. Read SEC document
January 05, 2021 Filed Jan 6, 2021 21:04 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionOrdinary Shares	41,615	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-002409 · doc4.xml · nonDerivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. Read SEC document
January 04, 2021 Filed Jan 6, 2021 21:04 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GrantRestricted Stock Units (RSU) · Derivative	27,942	$0.00	$0.00	Disclosure SEC source: 0001209191-21-002409 · doc4.xml · derivative · entry 5 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,942 Underlying: Ordinary Shares · 27,942 shares Expires not disclosed F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. F3 · derivative.expiration_date: The RSU's vest 1/3rd annually on each anniversary of January 5, 2020. Read SEC document
December 29, 2020 Filed Jan 22, 2021 21:00 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GiftOrdinary Shares	8,679	$0.00	$0.00	Disclosure SEC source: 0001209191-21-004993 · doc4.xml · nonDerivative · entry 2 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 183,634 Read SEC document
December 29, 2020 Filed Jan 22, 2021 21:00 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	GiftOrdinary Shares	8,679	$0.00	$0.00	Disclosure SEC source: 0001209191-21-004993 · doc4.xml · nonDerivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,008 Read SEC document
December 08, 2020 Filed Dec 9, 2020 17:05 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	31,133	$71.32	$2,220,405.56	Disclosure SEC source: 0001209191-20-062559 · doc4.xml · nonDerivative · entry 5 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 174,955 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 6, 2020. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.08 to $71.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 08, 2020 Filed Dec 9, 2020 17:05 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	9,631	$70.60	$679,948.60	Disclosure SEC source: 0001209191-20-062559 · doc4.xml · nonDerivative · entry 4 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 206,088 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 6, 2020. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.06 to 71.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 07, 2020 Filed Dec 9, 2020 17:05 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	10,489	$72.24	$757,725.36	Disclosure SEC source: 0001209191-20-062559 · doc4.xml · nonDerivative · entry 3 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 215,719 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 6, 2020. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.69 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 07, 2020 Filed Dec 9, 2020 17:05 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	16,200	$71.52	$1,158,624.00	Disclosure SEC source: 0001209191-20-062559 · doc4.xml · nonDerivative · entry 2 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 226,208 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 6, 2020. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.98 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
December 07, 2020 Filed Dec 9, 2020 17:05 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	36,389	$70.31	$2,558,510.59	Disclosure SEC source: 0001209191-20-062559 · doc4.xml · nonDerivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 242,408 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 6, 2020. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
October 21, 2020 Filed Oct 21, 2020 17:06 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionStock option (right to buy) · Derivative	13,000	$0.00 Strike: $7.61	$0.00	Disclosure SEC source: 0001209191-20-055485 · doc4.xml · derivative · entry 3 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 Underlying: Ordinary Shares · 13,000 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
October 21, 2020 Filed Oct 21, 2020 17:06 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionOrdinary Shares	13,000	$7.61	$98,930.00	Disclosure SEC source: 0001209191-20-055485 · doc4.xml · nonDerivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,015 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 21, 2020 Filed Oct 22, 2020 18:13 UTC Amendment	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionStock option (right to buy) · Derivative	13,000	$0.00 Strike: $7.61	$0.00	Disclosure SEC source: 0001209191-20-055602 · doc4a.xml · derivative · entry 3 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 Underlying: Ordinary Shares · 13,000 shares Expires 2024-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
October 21, 2020 Filed Oct 22, 2020 18:13 UTC Amendment	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionOrdinary Shares	13,000	$7.61	$98,930.00	Disclosure SEC source: 0001209191-20-055602 · doc4a.xml · nonDerivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,015 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 06, 2020 Filed Jul 7, 2020 18:49 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	9,100	$57.50	$523,250.00	Disclosure SEC source: 0001209191-20-041504 · doc4.xml · nonDerivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 278,797 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2020. Read SEC document
June 04, 2020 Filed Jun 5, 2020 01:06 UTC	XERIS PHARMACEUTICALS INC XERS · Entity 134906	GrantStock Option (right to buy) · Derivative	11,228	$0.00 Strike: $4.68	$0.00	Disclosure SEC source: 0000899243-20-015333 · doc4.xml · derivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,228 Underlying: Common Stock · 11,228 shares Expires 2030-06-04 F1 · derivative.exercise_date: Such options will vest in full upon the earlier to occur of June 4, 2021 or the date of the Company's next annual meeting of stockholders. Read SEC document
May 15, 2020 Filed May 18, 2020 20:51 UTC	Strongbridge Biopharma plc SBBP · Entity 131608	Tax withholdingOrdinary Shares	19,035	$2.86	$54,440.10	Disclosure SEC source: 0001179110-20-006241 · edgar.xml · nonDerivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,965 F1 · shares: Shares withheld by Strongbridge Biopharma plc to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units. Read SEC document
May 14, 2020 Filed May 15, 2020 21:10 UTC	Strongbridge Biopharma plc SBBP · Entity 131608	GrantOrdinary Shares	40,000	$0.00	$0.00	Disclosure SEC source: 0001179110-20-006109 · edgar.xml · nonDerivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 F1 · shares: Represents a grant of restricted stock units, which vest in full on May 14, 2021, provided that the Reporting Person continues to serve as a member of the board of directors of the Issuer through that date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
May 11, 2020 Filed May 12, 2020 16:12 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionStock option (right to buy) · Derivative	33,479	$0.00 Strike: $4.96	$0.00	Disclosure SEC source: 0001209191-20-028481 · doc4.xml · derivative · entry 4 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 33,479 shares Expires 2021-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
May 11, 2020 Filed May 12, 2020 16:12 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	SaleOrdinary Shares	33,479	$45.00	$1,506,555.00	Disclosure SEC source: 0001209191-20-028481 · doc4.xml · nonDerivative · entry 2 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,966 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2020. Read SEC document
May 11, 2020 Filed May 12, 2020 16:12 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionOrdinary Shares	33,479	$4.96	$166,055.84	Disclosure SEC source: 0001209191-20-028481 · doc4.xml · nonDerivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 11, 2020 Filed Mar 13, 2020 16:15 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionStock option (right to buy) · Derivative	5,287	$0.00 Strike: $12.94	$0.00	Disclosure SEC source: 0001209191-20-018857 · doc4.xml · derivative · entry 3 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,287 shares Expires 2020-06-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document
March 11, 2020 Filed Mar 13, 2020 16:15 UTC	Horizon Therapeutics Public Ltd Co HZNP · Entity 109157	Exercise / conversionOrdinary Shares	5,287	$12.94	$68,413.78	Disclosure SEC source: 0001209191-20-018857 · doc4.xml · nonDerivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · EVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 15, 2019 Filed May 16, 2019 20:13 UTC	Strongbridge Biopharma plc SBBP · Entity 131608	GrantOrdinary Shares	40,000	$0.00	$0.00	Disclosure SEC source: 0001179110-19-006153 · edgar.xml · nonDerivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 F1 · shares: Represents a grant of restricted stock units, which vest in full on May 15, 2020, provided that the Reporting Person continues to provide service as a member of the Board continuously from the Grant Date through such one-year anniversary. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document
February 27, 2019 Filed Mar 1, 2019 21:36 UTC	XERIS PHARMACEUTICALS INC XERS · Entity 134906	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $10.00	$0.00	Disclosure SEC source: 0000899243-19-005460 · doc4.xml · derivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-02-27 F1 · derivative.exercise_date: 25% of these shares shall vest on the first anniversary of the vesting commencement date, with the remainder vesting ratably over the following 36 months. Read SEC document
May 15, 2018 Filed May 17, 2018 12:41 UTC	Strongbridge Biopharma plc SBBP · Entity 131608	GrantStock Options (Right to Buy) · Derivative	40,000	$0.00 Strike: $7.75	$0.00	Disclosure SEC source: 0001179110-18-006951 · edgar.xml · derivative · entry 1 SHERMAN JEFFREY W · CIK 0001230482 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-05-15 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.